Sign of the Cross was the second novel by "New York Times" bestselling author Chris Kuzneski.
 First published in October 2006 by Penguin Group (USA), the religious thriller followed the exploits of Jonathon Payne and David Jones, who have been featured in all of Kuzneski's thrillers.
 It also introduced the character of Nick Dial, who has appeared in every Kuzneski novel since.
The Plantation was the first novel by Chris Kuzneski.
 First published in 2002, it introduced the characters of Jonathon Payne and David Jones, who have been featured in all of Kuzneski's thrillers.
 The book was endorsed by several notable authors, including James Patterson, Nelson DeMille, Lee Child, and James Rollins.
Flutamide, sold under the brand name Eulexin among others, is a nonsteroidal antiandrogen (NSAA) used primarily to treat prostate cancer.
 It acts as a selective antagonist of the androgen receptor (AR), competing with androgens such as testosterone and its powerful active metabolite dihydrotestosterone (DHT) for binding to ARs in the prostate gland.
 By doing so, it prevents them from stimulating the prostate cancer cells to grow.
 In addition to its use in prostate cancer, flutamide has been used to treat hyperandrogenism (excess androgen levels) in women, such as in those with polycystic ovary syndrome (PCOS), and hirsutism.
 Flutamide has been largely replaced by newer NSAAs, namely bicalutamide and enzalutamide, due particularly to better safety, tolerability, and pharmacokinetic profiles.
Vincent Joseph "Vince" Flynn (April 6, 1966 – June 19, 2013) was an American author of political thriller novels.
 He also served as a story consultant for the fifth season of the television series "24".
 He died on June 19, 2013, after a three-year battle with prostate cancer.
Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals for the treatment of prostate cancer.
 It inhibits AR-mediated gene transcription more potently than bicalutamide (by ~5- to 10-fold) and enzalutamide (by 2- to 5-fold) and maintains silent antagonism in castration-resistant prostate cancer (CRPC) cells.
 It has also been found to downregulate the AR, which could further confer it greater efficacy against CRPC compared to existing antiandrogens.
 Unlike enzalutamide, the drug showed low central nervous system (CNS) distribution and no induction of seizures in animals.
 As of 2017, it is in phase II clinical trials for prostate cancer.
 It is also in preclinical investigation for the treatment of AR-positive breast cancer.
The Hunters is a book series written by Chris Kuzneski, an American author.
 The series follows the adventures of a team of renegades – an ex-military leader, a historian, a computer whiz, a weapons expert and a thief – financed by a billionaire philanthropist who are tasked with finding the world's most legendary treasures.
 The first novel in the series, "The Hunters", is currently being turned into a motion picture, directed by John Moore with the screenplay being adapted by Robert Mark Kamen.
 The series also ties in with Kuzneski's other series, Payne & Jones, by featuring the character Petr Ulster, a historian and curator of the Ulster Archives in Küsendorf, Switzerland, and mentioning a number of minor characters and events from the Payne & Jones universe.
 The third book in the series, "The Prisoner's Gold", won the Thriller Award for the 2016 Book of the Year at a gala hosted by the International Thriller Writers (ITW) in New York City on July 9, 2016.
The Payne & Jones series is a collection of books written by Chris Kuzneski, an American author.
 The series follows the adventures of Jonathon Payne and David "D.J." Jones, former members of the MANIACs—an elite Special Forces unit in the U.S. military.
 Although the main characters are ex-soldiers, the novels are not “military” thrillers.
 The Payne & Jones series has loose ties with Chris Kuzneski's other series, The Hunters.
Sword of God was the third novel by "New York Times" bestselling author Chris Kuzneski.
 First published in September 2007 by Penguin Group (USA), the action thriller followed the exploits of Jonathon Payne and David "D.J." Jones as they slipped into the Islamic city of Mecca in order to rescue an American archaeologist.
 The book was endorsed by several notable authors, including Nelson DeMille, Vince Flynn, James Rollins, and Douglas Preston.
Abiraterone acetate (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal CYP17A1 inhibitor and by extension androgen synthesis inhibitor which is used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists.
 It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga.
 In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.
Indium (In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.
 Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue.
 It is linked to pendetide, a derivative of DTPA.
 Pendetide acts as a chelating agent for the radionuclide indium-111.
 Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).

Question: What is the name of the American author who died or prostate cancer and endorsed the Sword of God by Chris Kuzneski?
Answer: Vince Flynn